| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Modoflaner primarily targets gamma-aminobutyric acid (GABA)-gated chloride channels in the nervous system of parasites. It functions as a GABA-gated chloride channel blocker, allosterically modulating these channels and leading to increased neuronal excitability, paralysis, and death of target pests. This mechanism of action is characteristic of the meta-diamide class of insecticides.
|
|---|---|
| ln Vitro |
Modoflaner demonstrates significant insecticidal activity in vitro against a range of pests. At concentrations of 0.04, 0.2, and 1 μg/cm², it achieved over 90% mortality against ticks and fleas. In vitro injection tests (0.8, 0.16, and 0.32 μg/individual) showed 100% acaricidal activity. In vitro feeding tests at doses of 4, 0.8, 0.16, 0.032, and 0.064 ppm resulted in over 95% flea mortality. At 100 ppm, it exhibited over 70% mortality against Spodoptera litura, diamondback moth, and small brown planthopper.
|
| ln Vivo |
Modoflaner exhibits potent in vivo activity as an antiparasitic agent for controlling external parasites in animals, particularly fleas and ticks. It is effective in veterinary applications for pets (cats, dogs), poultry, and ornamental fish. As an agricultural insecticide, it demonstrates in vivo efficacy against lepidopteran pests (e.g., Helicoverpa armigera, rice stem borer, corn borer) and homopteran pests (e.g., planthoppers, aphids) on various crops including fruits, vegetables, and rice.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for modoflaner typically involve evaluating its interaction with GABA-gated chloride channels. These assays measure the compound's ability to allosterically modulate and block these channels, often using radioligand binding or electrophysiological techniques on insect neuronal membranes. The compound's binding affinity and inhibitory potency can be determined by assessing its effect on chloride ion flux or by measuring displacement of a known channel blocker.
|
| Cell Assay |
In vitro cellular assays for modoflaner involve treating cultured insect cells or parasite tissues with varying concentrations of the compound. Efficacy is assessed by measuring cell viability, paralysis, or mortality. For example, assays may use tick or flea cell lines, or primary cultures of insect neurons. The compound's ability to induce neuronal hyperexcitability and subsequent cell death is quantified, and EC50 or LC50 values are determined from dose-response curves.
|
| Animal Protocol |
In vivo animal experiments for modoflaner involve administering the compound to animal models infested with parasites (e.g., fleas, ticks) or to crop plants infected with pests. Efficacy is evaluated by measuring parasite mortality, reduction in infestation levels, or protection of crops from pest damage. Studies may involve topical application, oral administration, or injection, followed by monitoring of clinical signs and parasitological outcomes over a defined period.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for modoflaner are not extensively documented. As a lipophilic compound with a molecular weight of 715.23, it is expected to have good tissue penetration and systemic distribution following administration. The compound's long-lasting efficacy suggests a favorable pharmacokinetic profile with sustained exposure at target sites. Further studies are needed to fully characterize its absorption, distribution, metabolism, and excretion (ADME) properties in target animals.
|
| Toxicity/Toxicokinetics |
Toxicological data for modoflaner are limited in the available literature. As a meta-diamide insecticide targeting GABA-gated chloride channels, its selectivity for invertebrate versus vertebrate channels contributes to a favorable safety profile for mammals. The compound is intended for veterinary and agricultural use, with no reported human therapeutic applications. Standard safety precautions should be followed when handling this compound in research settings.
|
| References | |
| Additional Infomation |
Modoflaner (CAS#: 1331922-53-2) has the molecular formula C23H10F12IN3O2 and a molecular weight of 715.23. Its IUPAC name is 6-fluoro-N-[2-fluoro-3-[[4-(1,1,1,2,3,3,3-heptafluoropropan-2-yl)-2-iodo-6-(trifluoromethyl)phenyl]carbamoyl]phenyl]pyridine-3-carboxamide. The compound is not an approved therapeutic drug but is a research tool for studying parasite control and insecticidal mechanisms.
|
| Molecular Formula |
C23H10F12IN3O2
|
|---|---|
| Molecular Weight |
715.229719638824
|
| Exact Mass |
714.962
|
| CAS # |
1331922-53-2
|
| PubChem CID |
138490927
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
6.8
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
15
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
41
|
| Complexity |
932
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
IUJSREIEVDNHMT-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C23H10F12IN3O2/c24-15-5-4-9(8-37-15)18(40)38-14-3-1-2-11(16(14)25)19(41)39-17-12(21(27,28)29)6-10(7-13(17)36)20(26,22(30,31)32)23(33,34)35/h1-8H,(H,38,40)(H,39,41)
|
| Chemical Name |
6-fluoro-N-[2-fluoro-3-[[4-(1,1,1,2,3,3,3-heptafluoropropan-2-yl)-2-iodo-6-(trifluoromethyl)phenyl]carbamoyl]phenyl]pyridine-3-carboxamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : 100 mg/mL (139.82 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.3982 mL | 6.9908 mL | 13.9815 mL | |
| 5 mM | 0.2796 mL | 1.3982 mL | 2.7963 mL | |
| 10 mM | 0.1398 mL | 0.6991 mL | 1.3982 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
